<DOC>
	<DOCNO>NCT00427349</DOCNO>
	<brief_summary>RATIONALE : AMG 706 octreotide may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well AMG 706 octreotide work treat patient low-grade neuroendocrine tumor .</brief_summary>
	<brief_title>AMG 706 Octreotide Treating Patients With Low-Grade Neuroendocrine Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 4-month progression-free survival ( PFS ) patient low-grade neuroendocrine tumor treat AMG 706 octreotide acetate . Secondary - Determine response rate overall survival patient treat drug . - Determine toxicity tolerability AMG 706 patient . - Determine effect AMG 706 tumor perfusion functional computerized tomography ( CT ) scan . - Determine effect AMG 706 tumor marker ( e.g. , chromogranin A , 5-hydroxyindoleacetic acid , gastrin ) specific neuroendocrine tumor . - Determine effect AMG 706 serum vascular endothelial growth factor ( VEGF ) level . - Determine expression VEGF , VEGF receptor-2 ( VEGFR-2 ) , chromogranin A , human achaete-scute homolog-1 ( hASH1 ) , Notch1 marker neuroendocrine tumor . OUTLINE : This multicenter study . Patients receive oral AMG 706 octreotide acetate intramuscularly daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Plasma sample collect baseline , periodically study treatment , 4 week completion study treatment . Samples use determine plasma VEGF level . Gene expression downstream marker Raf kinase expression ( raf , MEK , ERK ) well hASH1 Notch1 evaluate baseline . Tumor tissue collect diagnosis prior surgery examine reverse transcriptase-polymerase chain reaction assay . Contrast CT scan conduct baseline , day 2 course 1 , week 8 assess tumor perfusion . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm lowgrade neuroendocrine neoplasm Measurable disease Radiographic evidence disease progression prior systemic therapy , chemoembolization , bland embolization , observation , define either follow : Appearance new lesion At least 20 % increase long diameter previously document lesion sum long diameter multiple lesion Tissue block original diagnostic surgical specimen require Concurrent stabledose octreotide acetate require Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Negative pregnancy test Fertile patient must use effective contraception Must able receive contrastenhanced CT scan Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 75,000/mm³ Hemoglobin level ≥ 8.0 g/dL Bilirubin ≤ 2.0 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ≤ 3 time ULN ( 5 time ULN liver metastasis present ) Left Ventricular Ejection Fraction ( LVEF ) ≥ institutional low limit normal evaluate echocardiography multigated acquisition ( MUGA ) scan No history uncontrolled hypertension ( rest blood pressure &gt; 150/90 mm Hg ) Antihypertensive medication allow patient stable current dose One prior systemic chemotherapy regimen lowgrade neuroendocrine neoplasm allow Chemoembolization consider systemic chemotherapy At least 4 week since prior major surgery , chemotherapy , radiation therapy , systemic therapy , local liver therapy Exclusion criterion : Prior procedure would adversely affect intestinal absorption Prior antivascular endothelial growth factor Concurrent chemotherapy radiation therapy History follow within past 12 month : New York Heart Association class III IV congestive heart failure Unstable angina pectoris Myocardial infarction Symptomatic cardiac arrhythmia Cerebrovascular accident transient ischemic attack Arterial venous thrombosis Known history allergic reaction AMG 706 derivative octreotide acetate injection Gastrointestinal tract disease result inability take oral medication ( i.e. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , bowel obstruction , inability swallow tablet ) Pregnant nurse Small cell lung cancer , medullary thyroid cancer , paraganglioma , pheochromocytoma Requirement intravenous alimentation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>localize gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>neuroendocrine tumor</keyword>
</DOC>